Badania kliniczne prowadzone w ośrodku Planetmed Sp. z o.o. (Ul. Lubinowa 12/8, Wrocław), które rekrutują lub wkrótce zaczną rekrutację. Dane pochodzą z rejestrów badań.
28 badań: 28 rekrutuje.
Ośrodek niezweryfikowany
Planetmed Sp. z o.o.
Ul. Lubinowa 12/8
Wrocław
Otwórz w Mapach Google · OpenStreetMap
Ośrodek niezweryfikowany. Nazwa, adres i lista badań pochodzą z publicznych rejestrów badań klinicznych (CTIS, ClinicalTrials.gov). Ośrodek nie potwierdził tych danych z nami. Przed wizytą zadzwoń do nas, a nasz doradca sprawdzi aktualne informacje.
Mapa: © autorzy OpenStreetMap
Wpisz słowo, żeby przeszukać wszystkie 28 badań.
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
+5A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
+5A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
+5A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
+4A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
+29A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
+3A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
+13Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
+7A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
+23A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
+15A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
+39Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
+9A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
+17Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
+21A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
+20A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
+8Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
+9A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
+3Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
+3Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
+1Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.